ClinicalTrials.gg
CompletedNCT01212445Updated Mar 15, 2016Results posted

Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)

A Phase 2 interventional study of PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430) in Constipation, sponsored by Bayer. Completed at 1 site in Ireland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-15.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing polyethylene glycol 3350 in Constipation — 3 open to participants now, 4 under way, none of them phase 3. polyethylene glycol 3350 · Constipation.

Enrollment
9th of 27
154 · median 100
Started
2010
with 1 other
Phase 2
2 of 27
none open now
Registered
13th of 27
by date
Lead sponsor
3 of 27
Bayer

Among the 27 studies testing polyethylene glycol 3350 in Constipation, this one is the 9th largest by enrollment, is one of 2 that started in 2010, is one of 2 in phase 2, and was the 13th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 27 studies testing polyethylene glycol 3350 in Constipation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About polyethylene glycol 3350

polyethylene glycol 3350: first FDA approval 1984 (GOLYTELY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing polyethylene glycol 3350 in Constipation, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the proportion of subjects with a bowel movement (BM) without straining or without hard and/or lumpy stool within the first 24 h of treatment for subjects taking 1 of 3 single doses of Polyethylene Glycol (PEG) plus Electrolytes (PEG+E) (13.125 g, 26.25 g, 39.375 g). The doses specified relate to the doses of PEG. Secondary objectives were measured by analysis of a subject diary and self-reported BM data. The secondary objectives included comparisons of PEG+E doses at 24 h for: BM control; relief of gas; relief of bloating; and relief of abdominal discomfort/cramping.

In addition, the proportion of subjects with a BM (without straining and without hard and/or lumpy stool) within the first 24 h of treatment for subjects taking different doses of PEG+E was evaluated for the time to first BM.

03

Conditions studied

  • Constipation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A willingness to participate in the study and comply with its procedures
  • Must be ambulatory
  • Male or female subjects aged 18 years or older who met two or more of the following modified Rome III-based criteria for constipation: (a) straining during at least 25% of defecations; (b) lumpy or hard stools in at least 25% of defecations; (c) sensation of incomplete evacuation for at least 25% of defecation; (d) sensation of anorectal obstruction/blockage for at least 25% of defecations; (e) manual maneuvers to facilitate at least 25% of defecations (eg, digital evacuation, support of the pelvic floor), and (f) fewer than 3 defecations per week
  • Criteria fulfilled for the last 3 months with symptom onset at least 6 mo prior to diagnosis
  • Had a self reported or documented history of chronic constipation
  • Agreed not to use laxatives other than the study treatment from baseline/ to end-of-study
  • Agreed to maintain a similar diet from the week before Visit 3 to the end-of-study were to be enrolled
  • Additionally required not to use any treatment known to cause constipation during the study (for subjects enrolled after Amendment 1)
  • If a female subject, either surgically sterile, 2 years , or using an acceptable method of . Abstinence was not an acceptable method of contraception. Females of had to have a urine pregnancy test (human chorionic gonadotropin [HCG]) that was negative at Visit 3
  • Be able to read and write in the diaries in English

Exclusion criteria

Exclusion Criteria:

  • Had loose stools without the use of laxatives
  • Recurrent abdominal pain
  • Known or suspected bowel perforation, obstruction, or fecal impaction; or had gastric retention, inflammatory bowel disease, bowel resection, or colostomy
  • Celiac disease or known gluten sensitivity
  • Known renal or hepatic insufficiency
  • Recent history of alcohol abuse or drug abuse
  • History of psychiatric disorders
  • History of significant ongoing medical problems or scheduled for surgical procedures
  • Subjects who, in the opinion of the Investigator, should not have been included in the study for any reason, including inability to follow study procedures
  • Participated in an clinical, surgical, drug or device study within the past 30 days
  • Pregnant or lactating
  • Allergic to PEG or PEG+E
  • Employed by or have immediate family members employed by a company that manufactures laxative products
  • Participant or family member of the Investigator or site staff directly involved with this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    PEG + E, 13.125 g

    Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time

    Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)

  • Experimental
    PEG + E, 26.25 g

    Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time

    Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)

  • Experimental
    PEG + E, 39.375 g

    Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time

    Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration

    A successful BM was defined as a BM with no straining or hard/lumpy stools.

    Time frame: From time of study drug treatment up to 24 hours

Secondary outcomes

  1. Number of Participants With Time To First Successful BM In 0 Days Through 0.5 Days, >0.5 Days Through 1.0 Days, or >1.0 Days Through 1.5 Days After PEG+E Administration

    Time to first successful bowel movement was defined as the duration (in days) from the time of first study dose of study treatment until first successful BM (defined as BM without straining and without hard and/or lumpy stool).

    Time frame: From time of study drug administration up to 3 Days

  2. Percentage of Participants With Successful BM Within 12 Hours of PEG+E Administration

    A successful BM was defined as a BM with no straining or hard/lumpy stools.

    Time frame: From time of study drug treatment up to 12 hours

  3. Mean Visual Analog Scale (VAS) Rating for BM Control

    The VAS is a psychometric response scale which measures responses along a continuum of values. The BM control VAS uses a 100 mm horizontal line with the two ends representing the opposite, extreme limits of the participant's experience of BM control. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. BM Control ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=Calm, not urgent and 100 mm= Not able to hold BM, very urgent. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group

    Time frame: From time of study drug treatment up to 24 hours

  4. Mean VAS Rating for Gas

    The VAS is a psychometric response scale which measures responses along a continuum of values. The Gas VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related gas. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Gas ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.

    Time frame: From time of study drug treatment up to 24 hours

  5. Mean VAS Rating for Bloating

    The VAS is a psychometric response scale which measures responses along a continuum of values. The Bloating VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related bloating. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Bloating ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.

    Time frame: From time of study drug treatment up to 24 hours

  6. Mean VAS Rating for Abdominal Discomfort/Cramping

    The VAS is a psychometric response scale which measures responses along a continuum of values. The Abdominal Discomfort/Cramping VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related abdominal discomfort/cramping. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Abdominal discomfort/cramping ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Painful. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.

    Time frame: From time of study drug treatment up to 24 hours

  7. Mean Participant Global Assessment of Treatment

    At the End of Study Visit, the study staff asked the participant to rate their global assessment of the study treatment according to the following categories: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective.

    Time frame: From time of study drug administration up to 2 Days

07

Results

Posted Mar 11, 2013

Participant flow

Participant flow — Overall Study
MilestonePEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Started525151
Completed525151
Not completed000

Outcome measures

PrimaryPercentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration

A successful BM was defined as a BM with no straining or hard/lumpy stools.

Time frame:
From time of study drug treatment up to 24 hours
Reported as:
Number · percentage of participants
Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration
percentage of participantsPEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration19.231.419.2
Statistical analysis
  • PEG + E 13.125 g vs PEG + E 26.25 g · Fisher Exact · p = 0.1790 · Treatment success rate: 0.192 · 95% CI 0.096 to 0.325
  • PEG + E 13.125 g vs PEG + E 39.375 g · Fisher Exact · p = 1.0000 · Treatment success rate: 0.314 · 95% CI 0.191 to 0.459
  • PEG + E 26.25 g vs PEG + E 39.375 g · Fisher Exact · p = 0.2558 · Treatment success rate: 0.196 · 95% CI 0.098 to 0.331
  • PEG + E 13.125 g vs PEG + E 26.25 g · Regression, Logistic · Odds ratio (or): 1.920 · 95% CI 0.774 to 4.763
  • PEG + E 13.125 g vs PEG + E 39.375 g · Regression, Logistic · Odds ratio (or): 1.024 · 95% CI 0.386 to 2.720
SecondaryNumber of Participants With Time To First Successful BM In 0 Days Through 0.5 Days, >0.5 Days Through 1.0 Days, or >1.0 Days Through 1.5 Days After PEG+E Administration

Time to first successful bowel movement was defined as the duration (in days) from the time of first study dose of study treatment until first successful BM (defined as BM without straining and without hard and/or lumpy stool).

Time frame:
From time of study drug administration up to 3 Days
Reported as:
Number · participants
Number of Participants With Time To First Successful BM In 0 Days Through 0.5 Days, >0.5 Days Through 1.0 Days, or >1.0 Days Through 1.5 Days After PEG+E Administration
participantsPEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Successful BM in 0 days through 0.5 days486
Successful BM in >0.5 days through 1.0 days684
Successful BM in >1.0 days through 1.5 days102
SecondaryPercentage of Participants With Successful BM Within 12 Hours of PEG+E Administration

A successful BM was defined as a BM with no straining or hard/lumpy stools.

Time frame:
From time of study drug treatment up to 12 hours
Reported as:
Number · percentage of participants
Percentage of Participants With Successful BM Within 12 Hours of PEG+E Administration
percentage of participantsPEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Percentage of Participants With Successful BM Within 12 Hours of PEG+E Administration7.715.711.8
Statistical analysis
  • PEG + E 13.125 g vs PEG + E 26.25 g · Fisher Exact · p = 0.2350 · Treatment success rate: 0.077 · 95% CI 0.021 to 0.185
  • PEG + E 13.125 g vs PEG + E 39.375 g · Fisher Exact · p = 0.5256 · Treatment success rate: 0.157 · 95% CI 0.070 to 0.286
  • PEG + E 26.25 g vs PEG + E 39.375 g · Fisher Exact · p = 0.7746 · Treatment success rate: 0.118 · 95% CI 0.044 to 0.239
  • PEG + E 13.125 g vs PEG + E 26.25 g · Regression, Logistic · Odds ratio (or): 2.233 · 95% CI 0.628 to 7.940
  • PEG + E 13.125 g vs PEG + E 39.375 g · Regression, Logistic · Odds ratio (or): 1.600 · 95% CI 0.424 to 6.043
SecondaryMean Visual Analog Scale (VAS) Rating for BM Control

The VAS is a psychometric response scale which measures responses along a continuum of values. The BM control VAS uses a 100 mm horizontal line with the two ends representing the opposite, extreme limits of the participant's experience of BM control. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. BM Control ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=Calm, not urgent and 100 mm= Not able to hold BM, very urgent. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group

Time frame:
From time of study drug treatment up to 24 hours
Reported as:
Mean · mm
Mean Visual Analog Scale (VAS) Rating for BM Control
mmPEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Mean Visual Analog Scale (VAS) Rating for BM Control31.1 ± 27.2723.5 ± 23.7629.4 ± 23.59
Statistical analysis
  • PEG + E 13.125 g vs PEG + E 26.25 g · ANCOVA · p = 0.1876 · Mean difference (final values): 7.752 · 95% CI -3.834 to 19.338
  • PEG + E 13.125 g vs PEG + E 39.375 g · ANCOVA · p = 0.7680 · Mean difference (final values): 1.706 · 95% CI -9.729 to 13.141
  • PEG + E 26.25 g vs PEG + E 39.375 g · ANCOVA · p = 0.2941 · Mean difference (final values): -6.046 · 95% CI -17.412 to 5.320
SecondaryMean VAS Rating for Gas

The VAS is a psychometric response scale which measures responses along a continuum of values. The Gas VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related gas. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Gas ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.

Time frame:
From time of study drug treatment up to 24 hours
Reported as:
Mean · mm
Mean VAS Rating for Gas
mmPEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Mean VAS Rating for Gas23.9 ± 21.8725.4 ± 27.1426.0 ± 22.93
Statistical analysis
  • PEG + E 13.125 g vs PEG + E 26.25 g · ANCOVA · p = 0.8109 · Mean difference (final values): -1.302 · 95% CI -12.059 to 9.454
  • PEG + E 13.125 g vs PEG + E 39.375 g · ANCOVA · p = 0.6995 · Mean difference (final values): -2.075 · 95% CI -12.693 to 8.544
  • PEG + E 26.25 g vs PEG + E 39.375 g · ANCOVA · p = 0.8850 · Mean difference (final values): -0.772 · 95% CI -11.329 to 9.784
SecondaryMean VAS Rating for Bloating

The VAS is a psychometric response scale which measures responses along a continuum of values. The Bloating VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related bloating. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Bloating ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.

Time frame:
From time of study drug treatment up to 24 hours
Reported as:
Mean · mm
Mean VAS Rating for Bloating
mmPEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Mean VAS Rating for Bloating33.9 ± 32.3921.7 ± 25.1032.7 ± 29.55
Statistical analysis
  • PEG + E 13.125 g vs PEG + E 26.25 g · ANCOVA · p = 0.0486 · Mean difference (final values): 12.886 · 95% CI 0.078 to 25.695
  • PEG + E 13.125 g vs PEG + E 39.375 g · ANCOVA · p = 0.8465 · Mean difference (final values): 1.245 · 95% CI -11.471 to 13.962
  • PEG + E 26.25 g vs PEG + E 39.375 g · ANCOVA · p = 0.0744 · Mean difference (final values): -11.641 · 95% CI -24.449 to 1.167
SecondaryMean VAS Rating for Abdominal Discomfort/Cramping

The VAS is a psychometric response scale which measures responses along a continuum of values. The Abdominal Discomfort/Cramping VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related abdominal discomfort/cramping. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Abdominal discomfort/cramping ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Painful. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.

Time frame:
From time of study drug treatment up to 24 hours
Reported as:
Mean · mm
Mean VAS Rating for Abdominal Discomfort/Cramping
mmPEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Mean VAS Rating for Abdominal Discomfort/Cramping17.4 ± 24.9114.0 ± 22.5614.5 ± 16.89
Statistical analysis
  • PEG + E 26.25 g · ANCOVA · p = 0.4591 · Mean difference (final values): 3.690 · 95% CI -6.153 to 13.534
  • PEG + E 13.125 g vs PEG + E 39.375 g · ANCOVA · p = 0.5546 · Mean difference (final values): 2.887 · 95% CI -6.765 to 12.539
  • PEG + E 26.25 g vs PEG + E 39.375 g · ANCOVA · p = 0.8685 · Mean difference (final values): -0.803 · 95% CI -10.397 to 8.790
SecondaryMean Participant Global Assessment of Treatment

At the End of Study Visit, the study staff asked the participant to rate their global assessment of the study treatment according to the following categories: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective.

Time frame:
From time of study drug administration up to 2 Days
Reported as:
Mean · units on a scale
Mean Participant Global Assessment of Treatment
units on a scalePEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 g
Mean Participant Global Assessment of Treatment1.0 ± 1.151.3 ± 1.261.2 ± 1.20
Statistical analysis
  • PEG + E 13.125 g vs PEG + E 26.25 g · ANCOVA · p = 0.1865 · Mean difference (final values): -0.311 · 95% CI -0.774 to 0.152
  • PEG + E 13.125 g vs PEG + E 39.375 g · ANCOVA · p = 0.5530 · Mean difference (final values): -0.139 · 95% CI -0.602 to 0.323
  • PEG + E 26.25 g vs PEG + E 39.375 g · ANCOVA · p = 0.4670 · Mean difference (final values): 0.172 · 95% CI -0.293 to 0.637

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG + E 13.125 g—0/52 (0%)0/52 (0%)
PEG + E 26.25 g—0/51 (0%)0/51 (0%)
PEG + E 39.375 g—0/51 (0%)0/51 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)PEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 gTotal
Mean45.9 ± 16.3150.4 ± 14.2743.3 ± 13.846.5 ± 14.85
Sex: Female, Male
Sex: Female, Male(Participants)PEG + E 13.125 gPEG + E 26.25 gPEG + E 39.375 gTotal
Female484441133
Male471021
08

Study locations

1 site
  • ORK, Ireland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2010
First posted
Sep 30, 2010
Start
Oct 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Mar 11, 2013
Last update
Mar 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01212445
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 30, 2010
Start date
Oct 2010
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Mar 11, 2013
Last update
Mar 15, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polyethylene glycol 3350 · Electrolytes · Polyethylene Glycols

Start the discussion